Takeda expands in Singapore
pharmafile | March 3, 2015 | News story | Manufacturing and Production | Singapore, Takeda, biopolis, emerging markets, vaccines
Japanese pharma giant Takeda has set up new Singapore offices in the Biopolis biomedical complex with the aim of expanding its emerging markets business.
The firm says Singapore’s geographical location and business environment allow it to focus on clinical development activities, educational initiatives and collaboration with commercial teams.
Speaking at an inauguration ceremony, Dr Beh Swan Gin, chairman of the Singapore Economic Development board, says: “EDB welcomes Takeda’s decision to make Singapore its emerging markets business unit headquarters. We are actively expanding the network and sophistication of professional services firms that support senior decision makers in these regional headquarters.”
Takeda has maintained a presence in the Asia-Pacific region for more than 50 years and entered Singapore in 2008. Operations in the area comprise 1,700 staff across 10 countries.
Along with an emerging markets unit the offices will also play host to the Takeda vaccine business unit and a regional R&D centre.
“Our new space in Singapore will allow us to more quickly address evolving market needs throughout the rapidly growing emerging markets, including Asia-Pacific,” says Giles Platford, president, emerging markets.
“It gives us close-to-door access to important market information that will help accelerate the development of medicines needed for battling regional and global health issues.”
The vaccine unit will host a laboratory for analytics and development of vaccines to protect against infectious diseases in the region, and coincidentally one of the firms vaccine offerings targets dengue fever which is soon to enter Phase III trials.
“Asia is a dynamic continent with four billion people across dozens of countries. Many Asian countries are facing the reality of rapidly aging populations and related health issues,” Platford adds.
“This move in Singapore places us to further strengthen Takeda’s commercial position and clinical development capabilities globally.”
Brett Wells
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
